Emergent, J&J settle COVID vaccine supply deal dispute

Emergent BioSolutions (EBS.N) said on Monday Johnson & Johnson (JNJ.N) has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter's COVID-19 vaccine.